Symrise (XTRA:SY1) shares have seen some movement recently, prompting fresh discussion among investors about its shifting valuation. With the past month showing a 10% gain, many are revisiting the stock’s potential as market conditions evolve.
See our latest analysis for Symrise.
Symrise has bounced back with a 1-month share price return of nearly 10%, reversing some of the losses seen earlier this year. Even so, the 1-year total shareholder return is still down over 27%. This suggests that while recent momentum is encouraging, many investors remain cautiously optimistic given the long-term underperformance.
If you want to broaden your search beyond Symrise, this could be the perfect time to discover fast growing stocks with high insider ownership
With analyst targets still well above the current share price, and growth estimates in the mix, the key question now is whether Symrise remains undervalued or if the recent recovery means the market already anticipates future gains.
With Symrise’s narrative fair value set at €103.53, shares closed at €81.82, highlighting a clear divergence between current sentiment and future expectations according to the prevailing view.
Symrise is executing a multi-year transformation focused on operational efficiency, portfolio optimization, and disciplined cost management, which is already yielding substantial margin improvements (notably, a gross margin increase of 250 bps and an EBITDA margin uplift). This is laying the groundwork for structurally higher net margins and improved earnings compounding.
Read the complete narrative.
Curious what’s fueling this bullish target? The secret mix includes aggressive margin upgrades, bold strategic initiatives, and forecasts that could reset investor expectations. See which financial levers might be game-changers, and what numbers experts are betting on to propel Symrise far above its current price.
Result: Fair Value of €103.53 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, slower growth in key end markets or underwhelming margin improvements could challenge the upbeat outlook and limit Symrise’s share price recovery.
Find out about the key risks to this Symrise narrative.
While Symrise looks undervalued on a fair value basis, its price-to-earnings ratio of 22.6x is higher than both European Chemicals peers (17.2x) and the peer average (20.4x). This is also above the fair ratio of 19.6x. This suggests a risk that the market may eventually pull the share price closer to these lower multiples. Does this signal an opportunity or a warning?